Jump to content

Search the Community

Showing results for tags 'Clinical trial'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 20 results

  1. Jim Marshall (not a doctor) said ... In this video Prostate Cancer Research Institute Executive Director Mark Scholz talks about a clinical trial for men who are metastatic and have rising psa on hormone therapy. The trial is testing whether adding the PARP inhibitor Lynparza (olaparib) to the super-hormone Zytiga (abiraterone) increases its effectiveness. You can find out about the clinical trial at: https://clinicaltrials.gov/ct2/show/study/NCT03732820?show_locs=Y#locn Details there include: inclusion details (things you need to get into the trial);
  2. The trial is titled "Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Strategies for PSMA Negative Disease". These clinical trials are headed by Prof. Michael Hofman and A/Prof. Arun Azad of Peter Mac. Recruiting is expected start early next year.Details of these trials will follow later this year. In essence, Lutetium will be given earlier in the piece, Lutetium will in special circumstances be given prior to robotic surgery, Research will commence into CAR T cell treatment for prostate cancer which is not PSMA avid and cannot currently be treated using Lutetiu
  3. Jim Marshall (not a doctor) said ... The clinical trial testing Lutetium-177 therapy against the existing standard therapy (Cabazitaxel (Jevtana)) is taking its first men. It starts at the Peter MacCallum Cancer Center in Melbourne (PeterMac), and other sites will be progressively added. The Prostate Cancer Foundation of Australia (PCFA), with which we are affiliated, has co-sponsored the trial. Below is the message that Daniel Moore of PCFA sent announcing the start. ... end Jim In July 2017 PCFA and ANZUP launched the first Australian trial of a ground-breaking
  4. Click here to read Malecare's report of a clinical trial which found that combining Xtandi and Zytiga and using them at the same time was NOT better then either of the drugs by themselves.
  5. "Bipolar Androgen Therapy" (BAT) involves alternately flooding and starving the body of the male hormone testosterone. Last year the forum had a post about a small study of 16 men which tested Bipolar Androgen Therapy: click here to read that previous post. The same researchers have now reported on a larger study with 47 Participants; click here to read about this study. Dr Matt Hobbs, deputy director of research at the charity Prostate Cancer UK, warned: "this is early stage research and further studies are needed in order to understand exactly how intrigu
  6. Several of our members have been participating in a clinical trial of Lutetium (Lu 177) being conducted at the Peter MacCallum Cancer Centre in Melbourne, Click here to read an article published in the Australian Financial Review about this clinical trial of Lutetium. A large randomised trial to test this treatment next year will be conducted in 2017.
  7. You may have heard on the news in the last day or so about how Keytruda, a drug used for melanoma, has produced good results in clinical trials to treat patients with lung cancer. Preliminary studies suggest that some advanced prostate cancer patients may respond well to Keytruda and futher clinical trials with prostate cancer patients are being planned. Click here to read a news article about the results of the clinical trials with Keytruda and lung cancer patients.
  8. At our phone-in meeting last Friday medical oncologist Professor Ken Ho and urologist Dr Ano Navaratnam spoke to us about their clinical trial looking to prevent and reverse the muscle wasting that occurs in men on hormone therapy (ADT). You will recall that the initial pilot phase of the trial is only available in Brisbane, Australia. Details Opportunity to Participate in World First Clinical Trial Are you a male who: • Has Prostate Cancer • On Androgen Deprivation (also known as “Hormones”) • Independent in yo
  9. Agenda Friday 26 August 2016 Please note This is a permanent change. We do not use 4444# any more. The phone numbers are unchanged. Urologist Ano Navaratnam (Urology Fellow Princess Alexandra and Greenslopes Hospital) and Medical Oncologist Ken Ho (Professor of Medicine, University of Queensland and Chair Centres for Health Research, Princess Alexandra Hospital, Brisbane) are conducting a clinical trial giving testosterone to men on hormone therapy (ADT). We are thrilled that they are both joining our phone-in meeting th
  10. Trial stopped - see below. Men who are on androgen deprivation therapy and who have metastases may be interested in the following Phase 3 clinical trial: A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC (ARMOR3-SV) Details of this trial are available at XXXXXXXXX To be eligible, you must not have been treated with abiraterone, enzalutamide or chemotherapy. You must have detectable AR-V7 (your circulating tumour cells will be tested as part of the eligibility process).
  11. Trial stopped - see below Thanks for Chuck Maack for alerting us to this. Galeterone (TOK-001) is a highly selective, multi-targeted, oral small molecule, drug candidate for the treatment of prostate cancer that disrupts androgen receptor (AR) signalling, the key driver of prostate cancer growth, via multiple mechanisms of action: androgen receptor degradation, which reduces the amount of androgen receptor protein in the tumor cells; inhibition of the enzyme CYP17, which blocks the synthesis of testosterone; and androgen receptor antagonism, which blocks th
  12. We've previously mentioned what an excellent resource the australianclinicaltrials.gov.au website is if you want to find out information about clinical trials. It has information about: What is a Clinical Trial? Why be part of a Clinical Trial? How to be part of a Clinical Trial? How to find a Clinical Trial? A new section called "Real Stories" with videos from participants in clinical trials has just been added. One of those "Real Stories" is a video about our Committee Member, Tony Maxwell.
  13. We are all familiar with the concept of intermittent ADT as opposed to continuous ADT. Now researchers are investigating the concept of intermittent chemotherapy as opposed to continuous chemotherapy. If certain criteria are met, there will a break in the chemotherapy treatment and the patient will have a “drug holiday”. In theory intermittent chemotherapy may serve 2 purposes. First, with less constant exposure to the drug, this may potentially delay the development of taxane-refractory disease. Second, breaks in therapy or “drug holidays” ma
  14. Sam Poley's father had aggressive and advanced prostate cancer. About a year ago Sam started a crowdfunding campaign to raise at least $1 million to fund a Phase II clinical trial to investigate the feasibility of using an FDA-approved and generally well-tolerated drug called disulfiram in the treatment of castration-resistant prostate cancer. Prostate Cancer needs copper—in fact, it’s a glutton for copper and will consume all it can get. This clinical trial will be designed to exploit that as a weakness Unfortunately Sam's dad has died but the appeal has raised $460,000 so far. Th
  15. The New Prostate Cancer Infolink has an article about the announcement of a new clinical trial of Enzalutamide (brand name Xtandi) in men with metastatic, hormone-sensitive prostate cancer. This trial will be recruiting men In Australia. The New Prostate Cancer Infolink expresses concern about the suitability of this trial for men newly diagnosed with a significant presence of metastatic disease. Click on this link to read the article.
  16. Paul Edwards

    New Clinical Trial of JNJ-56021927

    JNJ-56021927 (formerly known as ARN-509) is an androgen receptor antagonist. Some prostate cancer cells require androgens for growth. JNJ-56021927 prevent androgens from binding to the prostate cancer cells’ androgen receptors. JNJ-56021927 is not as advanced in its development as enzalutamide (Brand name Xtandi). Results from initial clinical trials suggest that JNJ-56021927 may be more potent and effective than enzalutamide. A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acet
  17. When should I consider a clinical trial? This 6 minute YouTube video answers this question. The doctors are from the MD Anderson Cancer Centre in the USA, but your Australian medical oncologist will also have access to many clinical trials. https://www.youtube.com/watch?v=sedcDN1JBWs
  18. In a surprising paradox, the male hormone testosterone, generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers and also may reverse resistance to testosterone-blocking drugs used to treat prostate cancer. A small study of 16 patients at the Johns Hopkins Kimmel Cancer Center was reported in the Jan. 7 issue of Science Translational Medicine. Larger studies are necessary before the treatment can be used outside clinical trials. Here is a link to a report in the HealthDay newsletter about the study: http://consumer.healthday.co
  19. Paul Edwards

    New Ipilimumab Trial in Australia

    Ipilimumab (brand name Yervoy) is an immunotherapy approach to the treatment of cancer. Ipilimumab was the first treatment ever proven to extend survival in patients with metastatic melanoma, the deadliest form of skin cancer, and has been approved by the Australian Pharmaceutical Benefits Scheme for that treatment. Ipilimumab was tested in two phase III trials as a treatment for advanced, castration-resistant prostate cancer. In the patients receiving Ipilimumab after docetaxel, the drug failed to improve overall survival. Results of the trial in which patients received Ipili
  20. PLATO is a 2 stage Clinical Trial with 500 patients (80% in Australia, rest in Finland, UK and USA). On Stage1 everyone gets Enzalutamide (no placebo). [Xtandi is the brand name for Enzalutamide] Those continuing in Stage 2 are randomised: 50% of patients to Abiraterone plus placebo and 50% of patients to Abiraterone plus Enzalutamide. Both arms in Stage 2 also get Prednisone to go with the Abiraterone. Stage 2 is double blind so neither doctor or patient know which arm you are in. Also in Stage 2 they do not do PSA tests but track the tumour w
×
×
  • Create New...